|Brand name(s), other common name(s)||EmplicitiTM|
|Drug type||Immunostimulatory antibody|
|How the drug is given||Injection|
Indications and Usage
Elotuzumab is FDA approved for the treatment of multiple myeloma
- In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.
- In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Side effects needing medical attention
Infusion reactions (such as fever, trouble breathing, chills, dizziness, rash, light-headedness); infections; risk of new cancers (malignancies); liver problems; fatigue; numbness, weakness, tingling, or burning pain in your arms or legs; diarrhea; sore throat or runny nose; fever; upper respiratory tract infection; constipation; decreased appetite; cough; pneumonia.